The emergence of HER2-targeted antibody-drug conjugates is transforming the management of metastatic HER2+ solid tumors, particularly in breast cancer, non-small cell lung cancer, gastroesophageal cancer, colorectal, and gynecological cancers. Tune in as experts take a deep dive into the latest evidence and guidelines on treatment sequencing and individualizing care for HER2+ cancers. Don’t miss the opportunity to learn how your patients can enroll in a personal health passport platform developed to facilitate patient involvement and shared decision-making in managing advanced and metastatic HER2+ cancers.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/exploring-her2-targeting-transforming-treatment-metastatic-locally-advanced
- Start Date: 2024-11-15 06:00:00
- End Date: 2024-11-15 06:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 41500.0 - Is Kind Support: False Source: Daiichi Sankyo, Inc. - Amount: 40000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest